Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9298853 | 1.00 | CES2 (0.52) | CES2CES1CYP2C9KMT2ACYP2C19 | |
| Hydrochloric Acid SCHEMBL75859 | 0.98 | CES2 (0.50) | CES2CES1CYP2C9KMT2ACYP2C19 | |
| SCHEMBL11638827 | 0.89 | PPARA (0.50) | CYP2C9KMT2ACYP2C19MEN1CYP2D6 | |
| Parachlorophenol SCHEMBL9108177 | 0.86 | CES2 (0.53) | CES2CES1CYP2C9KMT2ACYP2C19 | |
| SCHEMBL4016467 | 0.82 | CES2 (0.52) | CES2CES1CYP2C9KMT2ACYP2C19 | |
| SCHEMBL4018555 | 0.82 | CES2 (0.52) | CES2CES1CYP2C9KMT2AMEN1 | |
| SCHEMBL9298515 | 0.82 | BRD4 (0.45) | CES2CES1CYP2C9KMT2ACYP2C19 | |
| SCHEMBL5742269 | 0.82 | CES2 (0.46) | CES2CES1CYP2C9KMT2ACYP2C19 | |
| SCHEMBL75858 | 0.82 | BRD4 (0.45) | CES2CES1CYP2C9KMT2ACYP2C19 | |
| SCHEMBL234580 | 0.80 | CES2 (0.76) | CES2CES1KMT2ACYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102584621-B | Method for preparing mandipropamid | SHANDONG KANGQIAO BIO TECHNOLOGY CO LTD | 2014-12-03 | — | — | CN | claimed |
| CN-102584621-A | Method for preparing mandipropamid | JINAN KANGQIAO CHEMICAL CO LTD | 2012-07-18 | — | — | CN | claimed |
| WO-2007126258-A1 | THE METHOD OF MAKING OPTICALLY ACTIVE 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACID ESTERS AND 2-HALO-2-(N-SUBSTITUTED PHENYL)ACETIC ACIDS BY ENZYMATIC METHOD | ENZYTECH, LTD (KR) | 2007-11-08 | — | — | WO | claimed |
| EP-4720034-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | Zydus Lifesciences Limited (IN) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024252254-A1 | NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-12-12 | — | — | WO | disclosed |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4303216-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-01-10 | — | — | EP | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11702387-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-0067685-A1 | Alpha-phenyl-2-(aza)benzothiazolylthioglycolic acids and derivatives thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-12-22 | — | — | EP | disclosed |
| US-4327221-A | MODULATORS OF THE IMMUNE RESPINSE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-04-27 | — | — | US | disclosed |
| US-4307232-A | Preparation of dialkyl- and diarylphosphonoalkanoic acids and substituted acrylic acids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-12-22 | — | — | US | disclosed |
| US-4289697-A | 5-Substituted 4-hydroxy-2,3-alkylene thiazolium salts | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
| US-4275065-A | USEFUL FOR SKIN GRAFTS AND ORGAN TRANSPLANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| EP-0021773-A1 | Thiazolo (2,3-b) benzo (and azabenzo) thiazole derivatives, process for their preparation and pharmaceutical compositions containing them | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4053626-A | CHOLESTEROL LEVEL-LOWERING PHENOXYACETIC ACIDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-10-11 | — | — | US | disclosed |
| US-3992386-A | 4(Quinolyl)phenoxy alkanoic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3971828-A | METABOLISM, PROPHYLAXIS | SANTEN PHARMACEUTICAL CO. LTD. (JA) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | CES2 4024/4885CES1 2565/4885CYP2C9 1231/4885 |
| US-11702387-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | CES2 4024/4885CES1 2565/4885CYP2C9 1231/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | CES2 3497/4885CES1 376/4885CYP2C9 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.